What Pharmadrug does

PharmaDrug Inc. is a Canadian specialty pharmaceutical company publicly traded on the Canadian Securities Exchange under the symbol PHRX. Founded in 2011 and headquartered in Toronto, the company operates two divisions: Sairiyo Therapeutics, a majority-owned biotechnology subsidiary acquired in January 2021, and SecureDose, a wholly-owned division focused on synthetic drug formulations. The company is a pre-revenue clinical-stage developer focused on reformulated natural-based medicines for oncology and infectious diseases, alongside synthetic formulations of psychedelic compounds including DMT.

The company's lead asset is PD-001, a patented enteric-coated oral formulation of cepharanthine. The enteric coating is engineered to overcome the bioavailability limitations of the parent cepharanthine compound and has demonstrated 92-94% inhibition of Hantavirus pseudovirus infection in preclinical studies. The Sairiyo division houses the biotechnology development pipeline, while SecureDose targets synthetic formulations positioned around what the company characterizes as the third wave of drug policy reform. The company is also pursuing a planned May 2026 evaluation of PD-001 in Hantavirus and announced on October 30, 2025 its intent to acquire up to 40% equity in Canurta Inc., a botanical therapeutics company, in two tranches through January 2026.

Historically PharmaDrug operated as a medical cannabis importer and distributor in Germany and the EU through Pharmadrug GmbH, but that subsidiary was divested and the company pivoted toward pharmaceutical development. The company is currently pre-revenue with a lean team of 1-10 employees and finances operations through periodic capital raises, including a $650,000 non-brokered convertible secured debenture offering in August 2022 and a $445,686 convertible debenture restructuring in October 2025. Leadership includes David Kideckel as Chairman and Thomas Rabe as Managing Director.

Name

Pharmadrug

Legal name

PharmaDrug Inc.

Website

https://pharmadrug.co

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

PharmaDrug Inc. is a Canadian pre-revenue clinical-stage pharmaceutical company (CSE:PHRX) developing PD-001, a patented enteric-coated cepharanthine formulation for oncology and infectious diseases, alongside synthetic psychedelic drug formulations through its Sairiyo Therapeutics and SecureDose divisions.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

akta.pro secondary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Pharmaceutical development
• Natural-based medicines
• Oncology therapeutics
• Infectious disease treatments
• Synthetic drug formulations

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Product Development Revenue: Pre-revenue pharmaceutical company developing natural medicines, psychedelics, and cannabis-related products for clinical trials and regulatory approvals.

Marketing channels1 record

Core offering

PharmaDrug is a clinical-stage specialty pharmaceutical company that develops reformulated natural-based medicines for oncology and infectious diseases and develops synthetic formulations of existing drugs, with a focus on psychedelics. Its two operating divisions are Sairiyo Therapeutics (biotechnology, developing drug candidates such as PD-001, an enteric-coated oral formulation of cepharanthine) and SecureDose (synthetic formulation R&D). It is pre-revenue, with its drug candidates in preclinical/early-clinical evaluation targeting unmet therapeutic needs.

Product overview

PharmaDrug Inc. is a Canadian pharmaceutical company focused on two core divisions: Sairiyo Therapeutics (biotechnology) and SecureDose (synthetic formulation). Sairiyo Therapeutics develops reformulated natural-based medicines for unmet needs in oncology and infectious diseases, including its patented oral formulation PD-001 (enteric-coated cepharanthine). SecureDose focuses on developing synthetic formulations of existing drugs with a focus on potential third wave of drug policy reform. The company is also expanding its portfolio through the acquisition of up to 40% equity interest in Canurta Inc., a biotechnology firm specializing in botanical therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• Sairiyo Therapeutics: Biotechnology division focused on developing PD-001 (enteric-coated cepharanthine) and other therapeutic candidates for oncology and infectious diseases
• SecureDose

Products and services

• PD-001 (Enteric-Coated Cepharanthine) Patented oral formulation of cepharanthine being developed as a therapeutic candidate for infectious diseases, including evaluation for Hantavirus where it demonstrated 92–94% inhibition in preclinical studies. Targeted at patients with unmet medical needs in rare and emerging viral infections.
• DMT Psychedelic compound being developed as part of PharmaDrug's natural-medicine and psychedelics research program under its SecureDose synthetic formulation division. Intended for future clinical evaluation in indications relevant to drug-policy-reform contexts.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Canurta Inc.coreStrategic or Co-development Partner · 2 November 2025PharmaDrug announced it will acquire up to a 40% stake in Canurta, a biotech firm specializing in botanical therapeutics. The deal involves two closings expected in November 2025 and January 2026, subject to regulatory approvals. The transaction involves issuing up to 83,645,316 PharmaDrug shares for Canurta's limited partnership units.
• Sairiyo TherapeuticscoreOthers · 30 October 2025Majority-owned subsidiary of PharmaDrug focused on biotechnology and development of PD-001 cepharanthine for Hantavirus and other therapeutic applications.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Market position

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmadrug